Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antiviral drug |
| gptkbp:CASNumber |
3258-02-4
|
| gptkbp:chemicalFormula |
C9H13N3O6
|
| gptkbp:component |
gptkb:molnupiravir
|
| gptkbp:hasBiologicalActivity |
antiviral
|
| gptkbp:hasInChIKey |
XQSPYNMVSIKCOC-UUOKFMHZSA-N
|
| gptkbp:hasRole |
antiviral drug
investigational drug |
| gptkbp:hasSMILES |
C1=NC(=O)N(C(=N1)O)C2C(C(C(O2)CO)O)O
|
| https://www.w3.org/2000/01/rdf-schema#label |
N4-hydroxycytidine
|
| gptkbp:IUPACName |
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
|
| gptkbp:metabolism |
gptkb:molnupiravir
|
| gptkbp:molecularWeight |
259.22 g/mol
|
| gptkbp:parent |
cytidine
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103836
4539 |
| gptkbp:relatedTo |
cytidine
|
| gptkbp:synonym |
gptkb:NHC
EIDD-1931 N-hydroxycytidine β-D-N4-hydroxycytidine |
| gptkbp:target |
RNA viruses
|
| gptkbp:usedIn |
COVID-19 research
|
| gptkbp:bfsParent |
gptkb:Molnupiravir
|
| gptkbp:bfsLayer |
6
|